Bioventus Inc.
BVS
$6.55
$0.121.87%
NASDAQ
| 03/29/2025 | 12/31/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 567.70M | 573.28M | 555.06M | 536.89M | 522.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 567.70M | 573.28M | 555.06M | 536.89M | 522.74M |
| Cost of Revenue | 184.80M | 185.05M | 183.19M | 179.72M | 180.09M |
| Gross Profit | 382.90M | 388.23M | 371.87M | 357.17M | 342.65M |
| SG&A Expenses | 323.33M | 328.63M | 320.46M | 309.24M | 301.80M |
| Depreciation & Amortization | 7.49M | 7.65M | 7.99M | 8.24M | 8.47M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 529.67M | 535.00M | 525.32M | 510.09M | 502.66M |
| Operating Income | 38.03M | 38.28M | 29.75M | 26.81M | 20.09M |
| Income Before Tax | -47.47M | -49.53M | -58.16M | -61.52M | -26.42M |
| Income Tax Expenses | -6.30M | -5.29M | -6.59M | -6.58M | 1.14M |
| Earnings from Continuing Operations | -41.17 | -44.23 | -51.57 | -54.94 | -27.56 |
| Earnings from Discontinued Operations | -- | -- | 0.00 | 0.00 | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 9.56M | 10.37M | 11.77M | 12.66M | 5.59M |
| Net Income | -31.61M | -33.86M | -39.80M | -42.28M | -21.97M |
| EBIT | 38.03M | 38.28M | 29.75M | 26.81M | 20.09M |
| EBITDA | 80.04M | 80.21M | 73.60M | 72.21M | 67.01M |
| EPS Basic | -0.49 | -0.53 | -0.62 | -0.66 | -0.35 |
| Normalized Basic EPS | 0.18 | 0.17 | 0.09 | 0.06 | -0.13 |
| EPS Diluted | -0.49 | -0.53 | -0.62 | -0.66 | -0.35 |
| Normalized Diluted EPS | 0.18 | 0.17 | 0.09 | 0.06 | -0.13 |
| Average Basic Shares Outstanding | 260.78M | 258.15M | 255.80M | 253.36M | 251.86M |
| Average Diluted Shares Outstanding | 260.78M | 258.15M | 255.80M | 253.36M | 251.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |